College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Republic of Korea.
Clinical Vaccine R&D Center and Department of Microbiology, Chonnam National University Medical School, Republic of Korea.
Eur J Pharmacol. 2020 Oct 5;884:173407. doi: 10.1016/j.ejphar.2020.173407. Epub 2020 Jul 28.
Vibrio vulnificus (V. vulnificus) infection, frequently resulting in fatal septicemia, has become a growing health concern worldwide. The present study aimed to explore the potential agents that could protect against V. vulnificus cytotoxicity, and to analyze the possible underlying mechanisms. First, we observed that 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid disodium salt hydrate (DIDS) significantly suppressed V. vulnificus cytotoxicity to host cells by using a lactate dehydrogenase (LDH) assay. DIDS did not exhibit any effect on host cell viability, bacterial growth, microbial adhesion and swarming motility. DIDS effectively lowered V. vulnificus RtxA1 toxin-induced calcium influx into host mitochondria and RtxA1 binding to host cells. To further elucidate the underlying mechanism, the synthesis and secretion of RtxA1 toxin were investigated by Western blotting. Intriguingly, DIDS selectively inhibited the secretion of RtxA1 toxin, but did not influence its synthesis. Consequently, the outer membrane portal TolC, a key conduit for RtxA1 export coupled with tripartite efflux pumps, was examined by RT-PCR and Western blotting. We found that DIDS significantly reduced the expression of TolCV1 protein at the transcriptional level. Taken together, these results suggest that DIDS is a promising new paradigm as an antimicrobial drug that targets TolC-mediated toxin.
创伤弧菌(V. vulnificus)感染常导致致命性败血症,已成为全球日益关注的健康问题。本研究旨在探索可能对抗创伤弧菌细胞毒性的潜在药物,并分析其可能的作用机制。首先,我们通过乳酸脱氢酶(LDH)测定观察到 4,4'-二异硫氰酸根合二苯乙烯-2,2'-二磺酸二钠盐一水合物(DIDS)可显著抑制创伤弧菌对宿主细胞的细胞毒性。DIDS 对宿主细胞活力、细菌生长、微生物黏附和泳动运动没有任何影响。DIDS 能有效降低创伤弧菌 RtxA1 毒素诱导的宿主线粒体钙离子内流和 RtxA1 与宿主细胞的结合。为了进一步阐明其作用机制,我们通过 Western blot 研究了 RtxA1 毒素的合成和分泌。有趣的是,DIDS 选择性抑制 RtxA1 毒素的分泌,但不影响其合成。因此,我们通过 RT-PCR 和 Western blot 研究了外膜孔道 TolC,它是与三组分外排泵偶联的 RtxA1 外排的关键通道。我们发现 DIDS 可显著降低 TolCV1 蛋白在转录水平的表达。综上所述,这些结果表明 DIDS 是一种有前途的新型抗菌药物,可靶向 TolC 介导的毒素。